Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
Year: 2014
Type: article
Source: Annals of Oncology
Authors: F. Ciardiello, N. Normanno, E. Maiello, E. Martinelli, T. Troiani, S. Pisconti, F. Giuliani, C. Barone, G. Cartenì, A.M. Rachiglio, V. Montesarchio, G. Tonini, D. Rizzi, S. Cinieri, R. Bordonaro, A. Febbraro, F. De Vita, M. Orditura, F. Fenizia, M. Lambiase, A. Rinaldi, F. Tatangelo, G. Botti, G. Colucci
Institutions: University of Campania "Luigi Vanvitelli", Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Casa Sollievo della Sofferenza, Ospedale SS. Annunziata, Istituto Tumori Bari, Agostino Gemelli University Polyclinic, Ospedale Antonio Cardarelli, Ospedale Monaldi, Università Campus Bio-Medico, Ospedale A. Perrino, Ospedale Garibaldi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: metastatic colorectal cancer, FOLFIRI, cetuximab, anti-EGFR monoclonal antibody, KRAS exon 2 mutation, NRAS mutation, TP53 mutation, PIK3CA mutation, BRAF mutation, next-generation sequencing, predictive biomarkers, first-line therapy, treatment response, progression-free survival, RAS wild-type
Open Access status: bronze
OpenAlex ID: W2162247266
